The evolution of HER2-low-positive breast cancer as a clinical subtype

The evolution of HER2-low-positive breast cancer as a clinical subtype

#BREASTPATH Destiny of HER2/neu in the era of HER2-low in 2024Подробнее

#BREASTPATH Destiny of HER2/neu in the era of HER2-low in 2024

The evolution of HER2-low breast cancer from primary to recurrenceПодробнее

The evolution of HER2-low breast cancer from primary to recurrence

HER2-Low Expression in Breast Cancer: Opportunities for Expanding Treatment Benefit to More PatientsПодробнее

HER2-Low Expression in Breast Cancer: Opportunities for Expanding Treatment Benefit to More Patients

Defining HER2-low breast cancer as a clinical subtypeПодробнее

Defining HER2-low breast cancer as a clinical subtype

Is HER2-low a distinct subtype of breast cancer?Подробнее

Is HER2-low a distinct subtype of breast cancer?

HER2 Testing in Breast Cancer: Improving IHC PerformanceПодробнее

HER2 Testing in Breast Cancer: Improving IHC Performance

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment Approaches

ASCO Breast Cancer Update | Jane Meisel, MD | 2022 Review and Renew SedonaПодробнее

ASCO Breast Cancer Update | Jane Meisel, MD | 2022 Review and Renew Sedona

The Science of HER2-low Breast Cancer and Implications for the Pathology TeamПодробнее

The Science of HER2-low Breast Cancer and Implications for the Pathology Team

Dr. Aju Mathew, Assistant Professor of Medicine talking on Breast Cancer at our Foster City LabПодробнее

Dr. Aju Mathew, Assistant Professor of Medicine talking on Breast Cancer at our Foster City Lab

Kathy S. Albain: Patients with luminal A and B / HER2 negative breast cancerПодробнее

Kathy S. Albain: Patients with luminal A and B / HER2 negative breast cancer